Immunogenicity of Oxford-AstraZeneca COVID-19 vaccine in Vietnamese healthcare workers

Nguyen Van Vinh Chau¹, Lam Anh Nguyet², Nguyen Thanh Truong¹, Le Mau Toan¹, Nguyen Thanh Dung¹, Le Manh Hung¹, Mai Thanh Nhan¹, Dinh Nguyen Huy Man¹, Nghiem My Ngoc¹, Huynh Phuong Thao¹, Tran Nguyen Hoang Tu¹, Huynh Kim Mai³, Do Thai Hung², Nguyen Thi Han Ny³, Le Kim Thanh², Nguyen To Anh², Nguyen Thi Thu Hong², Le Nguyen Truc Nhu², Lam Minh Yen², Marc Choisy²,³, Tran Tan Thanh², Guy Thwaites²,³ and Le Van Tan², for OUCRU COVID-19 Research Group*

¹Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
²Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam
³Institute of Pasteur, Nha Trang City, Vietnam
⁴Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

*Members of the groups are listed in the acknowledgments.

Correspondence: Nguyen Van Vinh Chau, chaunvv@oucru.org, Le Van Tan, tanlv@oucru.org
List of groups prioritized for COVID-19 vaccination in Vietnam

1. Frontline healthcare workers of COVID-19, including people whose work is to deal with COVID-19 prevention and control work (members of COVID-19 steering committees at all levels, staff at state-run quarantine sites, people conducting contract tracing and epidemiological investigations, volunteers, reporters among others), military and public security forces

2. Vietnamese diplomats, customs and immigration officers

3. Essential service workers in sectors such as aviation, transport, tourism, electricity and water supply

4. Teachers and individuals working at education and training facilities, and those working at State agencies with regular contact with various people

5. People with chronic diseases or aging above 65

6. Residents in outbreak hotspots in Vietnam

7. Poor people, Policy beneficiaries

8. Those who will be sent abroad for learning and working

9. Other people determined by the Ministry of Health
**Supplementary Figure 1**: Probability of having detectable neutralizing antibodies among the study participants selected for assessment of the impact of the second dose. **A)** At 2 and 4 weeks after the first dose (n=104), **B)** Before the second dose (i.e. 6 weeks after the first dose) and 2 weeks after the second dose (n=104) and **C)** at month 3 after the first dose (n=94). Shaded areas indicate 95% of confident intervals.
Supplementary Figure 2: Association between neutralizing antibody levels and gender. 
A) At 2 and 4 weeks after the first dose of the whole group (n=554), B) From baseline to month three after the first dose of the subgroup.